LZLing Zhang

Ling Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ling Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaohui Liao

    The Second Affiliated Hospital, Chongqing Medical University

    3 shared publications
  • Chenli Zhang

    Department of Nephrology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China

    2 shared publications
  • Jun Deng

    Institute of Burn Research Southwest Hospital State Key Lab of Trauma and Chemical Poisoning Army Medical University Chongqing China

    2 shared publications
  • Pengfei Yang

    Department of Nephrology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China

    2 shared publications
  • Zeli Xiang

    Department of nephrology, Second People’s Hospital of Yibin, Yibin, China

    2 shared publications
  • Lili Huang

    Department of Nephrology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China

    1 shared publication

Latest Publications

  • Open Access

    Renal-tubular-mitochondrial sequentially targeted nanoagent breaks the vicious cycle of oxidative stress and mtDNA-driven inflammation in acute kidney injury therapy

    by Chenli Zhang, Ling Tan, Pengfei Yang, Lili Huang, Zeli Xiang, Lingshan Zhao, Ling Zhang, Jun Deng, Xiaohui Liao

    Acute kidney injury (AKI) is a life-threatening disorder that is responsible for 1.7 million deaths each year. Current treatment strategies, such as renal replacement therapy and supportive care, remain ineffective in reversing tubular damage in 20–50% of patients, largely due to their inability to promptly restore renal tubular epithelial cells function. The present study developed a cascade-targeted core-shell nanotherapeutic agent STMB with L-serine shell that enables precise kidney injury molecule 1-mediated delivery to damaged RTECs, while tannic acid core facilitates mitochondrial localization. Tannic acid continuously scavenges reactive oxygen species. By simultaneously clearing reactive oxygen species and preventing mitochondrial DNA leakage by STMB, this dual-channel intervention successfully terminates the self-amplifying cycle of oxidative damage and inflammatory signaling, resulting in therapeutic effects in both cisplatin-induced and ischemia-reperfusion AKI models. This strategy redefines AKI therapeutics by transitioning from passive symptom management to active cellular repair, which fills a critical void in clinical nephrology and opens new avenues for organ-protective nanomedicine development in critical care settings. Graphical Abstract


  • Open Access

    Advances in Nano‐Immunomodulatory Systems for the Treatment of Acute Kidney Injury

    by Chenli Zhang, Zeli Xiang, Pengfei Yang, Ling Zhang, Jun Deng, Xiaohui Liao

    Acute kidney injury (AKI) occurs when there is an imbalance in the immune microenvironment, leading to ongoing and excessive inflammation. Numerous immunomodulatory therapies have been suggested for the treatment of AKI, the current immunomodulatory treatment delivery systems are suboptimal and lack efficiency. Given the lack of effective treatment, AKI can result in multi‐organ dysfunction and even death, imposing a significant healthcare burden on both the family and society. This underscores the necessity for innovative treatment delivery systems, such as nanomaterials, to better control pathological inflammation, and ultimately enhance AKI treatment outcomes. Despite the modification of numerous immunomodulatory nanomaterials to target the AKI immune microenvironment with promising therapeutic results, the literature concerning their intersection is scarce. In this article, the pathophysiological processes of AKI are outlined, focusing on the immune microenvironment, discuss significant advances in the comprehension of AKI recovery, and describe the multifunctionality and suitability of nanomaterial‐based immunomodulatory treatments in managing AKI. The main obstacles and potential opportunities in the swiftly advancing research field are also clarified.